Internal Medicine, Medical Oncology · Philadelphia, PA
NPI
1316975451
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
3
Medicare group memberships
Hospitals
4
Hospital affiliations
10800 Knights Rd Fl 3
Philadelphia, PA, 19114
Phone (215) 890-3030
Groups this clinician bills Medicare through
Medicare paid, 2024
$46K
425 services
Medicare patients, 2024
112
Average age 73
Drug cost, 2024
$8.3M
858 prescriptions
Company payments, 2025
$16K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Marcia S Brose was code 99215 (office e&m - established), 248 times for 95 patients. In total Marcia S Brose billed 425 services in 11 codes, and Medicare paid $46K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-11-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 248 | 95 | $137.20 | $34K |
| 99214 Office E&M - Established | Office | 91 | 62 | $99.24 | $9,031 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 67 | 48 | $13.05 | $874 |
By year: 2022 $53K for 365 services; 2023 $47K for 360 services; 2024 $46K for 425 services.
Medicare prescription drug claims, 2024
In 2024, the drug Marcia S Brose prescribed most often to Medicare patients was Lenvima (Lenvatinib Mesylate), with 210 prescriptions and refills. In total Marcia S Brose wrote 858 Medicare prescriptions that cost $8.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Lenvima Lenvatinib Mesylate | 210 | 219 | 25 | $5.1M |
| Levothyroxine Sodium Generic | 138 | 411 | 39 | $2,789 |
| Synthroid Levothyroxine Sodium | 60 | 145 | 15 | $5,471 |
| Cabometyx Cabozantinib S-Malate | 49 | 49 | Under 11 | $1.8M |
| Amlodipine Besylate Generic | 32 | 94 | Under 11 | $316 |
| Loperamide Loperamide Hcl | 22 | 24 | Under 11 | $823 |
| Tafinlar Dabrafenib Mesylate | 21 | 21 | Under 11 | $286K |
| Gabapentin Generic | 19 | 40 | Under 11 | $193 |
| Citalopram Hbr Citalopram Hydrobromide | 19 | 51 | Under 11 | $127 |
| Oxycodone Hcl Generic | 18 | 18 | Under 11 | $170 |
| Furosemide Generic | 16 | 46 | Under 11 | $57.17 |
| Lisinopril Generic | 14 | 42 | Under 11 | $144 |
| Calcitriol Generic | 13 | 39 | Under 11 | $324 |
| Vitrakvi Larotrectinib Sulfate | 12 | 12 | Under 11 | $470K |
| Ibuprofen Generic | 11 | 11 | Under 11 | $81.16 |
Brand drugs: 443 claims; generic drugs: 415 claims; opioid claims: 41.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Marcia S Brose $16K ($16K in general payments such as food, travel and fees) from 8 companies. The largest payer was Eisai Inc. with $11K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.